Author details

Full Name

Shunqiang Li

Affiliation

ORCID

Career Start Year

2005

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36470535	Proteins in Tumor-Derived Plasma Extracellular Vesicles Indicate Tumor Origin.	Molecular and Cellular Proteomics	2023
37034206	Crizotinib induces Par-4 secretion from normal cells and GRP78 expression on the cancer cell surface for selective tumor growth inhibition.	Am J Cancer Res	2023
37272756	Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21-CDK4/6-Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance.	Cancer Res	2023
36961012	Animal Models and Their Role in Imaging-Assisted Co-Clinical Trials.	Tomography	2023
37071495	Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer.	Cancer Res	2023
34996889	Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment.	Nat Commun	2022
36001024	Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer.	Cancer Discov	2022
36395883	Diptoindonesin G is a middle domain HSP90 modulator for cancer treatment.	Journal of Biological Chemistry	2022
36561964	PROSER2 is a poor prognostic biomarker for patients with osteosarcoma and promotes proliferation, migration and invasion of osteosarcoma cells.		2022
36619972	Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach.	iScience	2022
34328530	Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer.	Eur J Nucl Med Mol Imaging	2022
34782721	Correction to: Hormonal modulation of ESR1 mutant metastasis.	Oncogene	2022
34550428	Correction to: Coâ¿¿clinical FDGâ¿¿PET radiomic signature in predicting response to neoadjuvant chemotherapy in tripleâ¿¿negative breast cancer.	Eur J Nucl Med Mol Imaging	2022
34359696	Deep Learning Segmentation of Triple-Negative Breast Cancer (TNBC) Patient Derived Tumor Xenograft (PDX) and Sensitivity of Radiomic Pipeline to Tumor Probability Boundary.	Cancers (Basel)	2021
33591953	Chromosome 8 gain is associated with high-grade transformation in MPNST.	JCI Insight	2021
33542078	Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer.	Clinical Cancer Research	2021
34011995	Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer.	Nature Communications	2021
33257837	RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer.	Br J Cancer	2021
33355448	Hyaluronan-Conjugated Carbon Quantum Dots for Bioimaging Use.	ACS applied materials & interfaces	2021
34902246	Macrocyclic Inhibitors of HGF-Activating Serine Proteases Overcome Resistance to Receptor Tyrosine Kinase Inhibitors and Block Lung Cancer Progression.	Journal of Medicinal Chemistry	2021
34711608	Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer.	Cancer Res	2021
34429404	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment.	Nat Commun	2021
32891051	Optimal co-clinical radiomics: Sensitivity of radiomic features to tumour volume, image noise and resolution in co-clinical T1-weighted and T2-weighted magnetic resonance imaging.	eBioMedicine	2020
32165732	Selective imaging of solid tumours via the calcium-dependent high-affinity binding of a cyclic octapeptide to phosphorylated Annexin A2.	Nature Biomedical Engineering	2020
31757841	Preclinical PERCIST and 25% of SUV<sub>max</sub> Threshold: Precision Imaging of Response to Therapy in Co-clinical <sup>18</sup>F-FDG PET Imaging of Triple-Negative Breast Cancer Patient-Derived Tumor Xenografts.	J Nucl Med	2020
33371187	Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models.	Cancers (Basel)	2020
31196969	Regulated Phosphosignaling Associated with Breast Cancer Subtypes and Druggability.	Mol Cell Proteomics	2019
31572793	Test-Retest Performance of a 1-Hour Multiparametric MR Image Acquisition Pipeline With Orthotopic Triple-Negative Breast Cancer Patient-Derived Tumor Xenografts.	Tomography	2019
30518672	Cooperative Effect of Oncogenic <i>MET</i> and <i>PIK3CA</i> in an HGF-Dominant Environment in Breast Cancer.	Mol Cancer Ther	2019
31217901	PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer.	Oncotarget	2019
31074257	Assessment of Copper Nanoclusters for Accurate in Vivo Tumor Imaging and Potential for Translation.	ACS applied materials & interfaces	2019
31369274	Folate Receptor Î±-Targeted Zr-M9346A Immuno-PET for Image-Guided Intervention with Mirvetuximab Soravtansine in Triple-Negative Breast Cancer.	Molecular Pharmaceutics	2019
29326282	RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells.	Clinical Cancer Research	2018
30089255	Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer.	Cell Rep	2018
29748621	Proteomic profiling identifies key coactivators utilized by mutant ERÎ± proteins as potential new therapeutic targets.	Oncogene	2018
29472518	Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers.	Cancer Res	2018
29291741	Identifying biomarkers of breast cancer micrometastatic disease in bone marrow using a patient-derived xenograft mouse model.	Breast Cancer Res	2018
28209615	Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer.	Cancer Research	2017
28348404	Proteogenomic integration reveals therapeutic targets in breast cancer xenografts.	Nat Commun	2017
28801307	Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.	Cancer Discov	2017
28619968	Breast Cancer Neoantigens Can Induce CD8<sup>+</sup> T-Cell Responses and Antitumor Immunity.	Cancer Immunol Res	2017
28790197	Breast tumors educate the proteome of stromal tissue in an individualized but coordinated manner.	Sci Signal	2017
28440318	Corrigendum: Proteogenomic integration reveals therapeutic targets in breast cancer xenografts.	Nat Commun	2017
29262642	Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent.	Oncotarget	2017
29124938	Quality Assessments of Long-Term Quantitative Proteomic Analysis of Breast Cancer Xenograft Tissues.	J Proteome Res	2017
28025748	Patient-derived xenograft (PDX) models in basic and translational breast cancer research.	Cancer Metastasis Rev	2016
27486754	Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer.	Oncotarget	2016
26653538	Reproducibility of Differential Proteomic Technologies in CPTAC Fractionated Xenografts.	J Proteome Res	2016
26598639	QuantFusion: Novel Unified Methodology for Enhanced Coverage and Precision in Quantifying Global Proteomic Changes in Whole Tissues.	Molecular and Cellular Proteomics	2016
26503891	Integrated Bottom-Up and Top-Down Proteomics of Patient-Derived Breast Tumor Xenografts.	Mol Cell Proteomics	2016